Cap Raising News:A new way of raising for a Hopper-company but...

Cap Raising News:

A new way of raising for a Hopper-company but this time it is a good one:

CHM AUD 4m

$4.0m Non-Dilutionary Funding
• US-based family office provides ~A$4.0 million in non-dilutionary funding for
development of CHM CDH17 CAR-T
Melbourne, Australia, 27 February 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, is pleased to announce the receipt of nondilutionary funding.
US Family Office Funding ~A$4.0 million
Chimeric is pleased to announce that it has received US$2.5 million (~A$4.0 million) in nondilutionary funding for the development of CHM CDH17 from an undisclosed US-based
philanthropic family office.
Chimeric’s CEO, Dr Rebecca McQualter, said: “This is a solid confirmation of the great promise of
our CHM CDH17 technology and we are very appreciative of the confidence shown.”
The funds have been received, are non-refundable and there is no further obligation on the
philanthropic family office. There is no transfer of intellectual property or issue of equity to the
philanthropic family office. The Company does not consider the identity of the philanthropic
family office to be information that a reasonable person would expect to have a material effect
on the price or value of the entity’s Company’s securities. The Company confirms that this
announcement contains all material information regarding the funding and is not misleading by
omission